Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HDM1005 Gastric Emptying and DDI Study in Overweight/Obese Adult Chinese Subjects
NCT07502001Phase 1Not yet recruiting
- Sponsor
- Huadong Medicine
- Start
- Apr 2026
- Primary completion
- Dec 2026
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of poterepatide in obesity, sponsored by Huadong Medicine. Primary endpoints: Area Under the Concentration Time Curve From Time Zero to Infinity, Maximum observed concentration and 2 more. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
poterepatide
03
Conditions
obesity
Beyond the preview
Go deeper on NCT07502001.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07502001.